Formycon AG (FYB.DE) – Market Snapshot & Strategic Development Move
Intraday performance
The share price closed 4.33 % lower at 05:08 PM CET on Wednesday, 21 October 2026, trading at EUR 19.64.
The 24‑hour trading volume amounted to EUR 54.3 k, against a circulating supply of 17.7 million shares.
Market capitalization stands at EUR 345 million.
Over the last month, the stock has fallen 1.14 %.
The 200‑day simple moving average is EUR 20.01; the 52‑week high was EUR 26.95 (01 May 2026) while the 52‑week low was EUR 15.80 (23 March 2026).
Strategic partnership announcement Formycon AG has entered a biosimilar development collaboration with Uruguay‑based specialty pharma firm Biocelys.
The joint venture centers on the candidate FYB286, a biosimilar targeting a niche indication with strong upside potential.
Formycon will supply its established development platform; Biocelys will contribute advanced manufacturing capabilities that enable a competitive cost structure.
The initiative is pre‑financed by Santo Biosimilar GmbH, an affiliate of the ATHOS Group, which also holds indirect control over Biocelys.
Under the terms, Formycon receives standard market compensation for development services and a modest share of future revenues.
This partnership aligns with Formycon’s broader growth strategy: portfolio diversification, geographic expansion, scientific excellence, and efficient cost management.
Related equity activity (last 24 hours)
| Ticker | Movement | Current Price | Market Cap | Key Metric |
|---|---|---|---|---|
| DR0.DE (Deutsche Rohstoff) | –0.48 % | EUR 85.7 | EUR 404.6 m | P/E = 2.71 |
| WBAH.F (Wild Bunch) | 0 % | EUR 15.2 | EUR 363.9 m | – |
| M12.DE (M1 Kliniken) | –2.77 % | EUR 19.72 | EUR 363.7 m | P/E = 18.1 |
| PBB.DE (Deutsche Pfandbriefbank) | +0.9 % | EUR 2.91 | EUR 387.3 m | Short‑sale disclosures by Citadel, Millennium, etc. |
Contextual outlook Despite a modest intraday dip, Formycon’s partnership with Biocelys injects fresh growth prospects into its biosimilar pipeline. The pre‑financing by Santo Biosimilar GmbH mitigates immediate cash flow pressure, while the collaboration leverages Biocelys’ cost‑efficient manufacturing to accelerate time‑to‑market. For investors monitoring the sector, the 200‑day moving average proximity and the recent price action suggest a consolidation phase before a potential rebound, especially as the company’s strategic initiatives unfold.
Company profile Formycon AG, with over twelve years of experience, specializes in developing and marketing biosimilars—biopharmaceuticals that mirror patent‑expiring reference products. Additionally, it offers contract development services to other biotechnology and pharmaceutical entities, reinforcing its position as a versatile player in the biopharma landscape.
